De Clercq E
Rega Institute for Medical Research, KULeuven, Minderbroedersstraat 10 - B-3000 Leuven.
Verh K Acad Geneeskd Belg. 2007;69(2):81-104.
There are, at present, 22 compounds which have been formally approved (by the US Food and Drug Administration) for the treatment of HIV infections (AIDS). According to their point of intervention with the HIV replicative cycle, these compounds can be classified in 5 categories: (1) NRTIs (nucleoside reverse transcriptase inhibitors): azidothymidine, didanosine, zalcitabine, stavudine, lamivudine, abacavir and emtricitabine; (2) NtRTIs (nucleotide reverse transcriptase inhibitors): tenofovir, administered as its oral prodrug form TDF (tenofovir disoproxil fumarate); (3) NNRTIs (non-nucleoside reverse transcriptase inhibitors): nevirapine, delavirdine and efavirenz; (4) PIs (HIV protease inhibitors): saquinavir, ritonavir, indinavir, nelfinavir, amprenavir, lopinavir, atazanavir, fosamprenavir, tipranavir and darunavir; and (5) FIs (fusion inhibitors): enfuvirtide. Starting from the drugs which are currently available for the treatment of AIDS, numerous combinations could be envisaged. Drug combinations are, in principle, aimed at obtaining synergism between the compounds (reasonably expected if they act by different mechanisms), while reducing the likelihood for drug resistance development. Such anti-HIV drug combination regimes were initiated about 10 years ago and have been generally referred to as HAART (for highly active antiretroviral therapy). While HAART originally consisted of a pill burden of twenty (or more) pills per day, this has been gradually diminished over the past few years, and, since July 2006, a all-in-one pill (Atripla) has become available, which contains three anti-HIV drugs (tenofovir disoproxil fumarate, emtricitabine and efavirenz) to be taken as a single pill only once daily. Given the information that has been acquired on the therapeutic use (efficacy, safety) of tenofovir disoproxil fumarate over the past five years, it would now seem mandatory to further consider the prophylactic use of TDF [and its combination with emtricitabine (Truvada) and/or Atripla], as a single daily pill to prevent HIV infection.
目前,已有22种化合物(经美国食品药品监督管理局正式批准)用于治疗HIV感染(艾滋病)。根据它们在HIV复制周期中的干预点,这些化合物可分为5类:(1)核苷类逆转录酶抑制剂(NRTIs):齐多夫定、去羟肌苷、扎西他滨、司他夫定、拉米夫定、阿巴卡韦和恩曲他滨;(2)核苷酸类逆转录酶抑制剂(NtRTIs):替诺福韦,以其口服前体药物形式TDF(替诺福韦酯富马酸盐)给药;(3)非核苷类逆转录酶抑制剂(NNRTIs):奈韦拉平、地拉韦啶和依非韦伦;(4)HIV蛋白酶抑制剂(PIs):沙奎那韦、利托那韦、茚地那韦、奈非那韦、安普那韦、洛匹那韦、阿扎那韦、福沙那韦、替拉那韦和达芦那韦;以及(5)融合抑制剂(FIs):恩夫韦肽。从目前可用于治疗艾滋病的药物出发,可以设想出众多的组合。药物组合原则上旨在实现化合物之间的协同作用(如果它们通过不同机制起作用,则合理预期会有协同作用),同时降低耐药性产生的可能性。这种抗HIV药物联合治疗方案大约在10年前开始实施,通常被称为高效抗逆转录病毒治疗(HAART)。虽然HAART最初每天的服药量为20片(或更多),但在过去几年中已逐渐减少,自2006年7月以来,出现了一种三合一药丸(Atripla),它含有三种抗HIV药物(替诺福韦酯富马酸盐、恩曲他滨和依非韦伦),只需每天服用一片。鉴于在过去五年中已获得的关于替诺福韦酯富马酸盐治疗用途(疗效、安全性)的信息,现在似乎有必要进一步考虑将TDF[及其与恩曲他滨(Truvada)和/或Atripla的组合]作为每日一片的单一药丸用于预防HIV感染。